CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Editorial Board

Arthur J. Atkinson, Jr., M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Edward A. Carr, Jr., M.D.
Leighton E. Cluff, M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Henry W. Elliott, M.D., Ph.D.
Karl Engelman, M.D.
Alvan R. Feinstein, M.D.
Max Fink, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Franz Gross, M.D.
Arthur Hull Hayes, Jr., M.D.
Leo E. Hollister, M.D.
Bartholomew P. Hsi, Ph.D.
Murray E. Jarvik, M.D.
Ernest Jawetz, M.D., Ph.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Joseph B. Kirsner, M.D., Ph.D.
Kenneth G. Kohlstaedt, M.D.
Louis Lasagna, M.D.
D. R. Laurence, M.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
Daniel S. Lukas, M.D.
Fletcher H. McDowell, M.D.
Dean T. Mason, M.D.
R. K. Richards, M.D.
Jay Tepperman, M.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.
Graham M. Wilson, M.D., F.R.C.P., F.R.C.P.E.

Volume 18, July-December, 1975
The C. V. Mosby Company, St. Louis

Volume 18
Copyright © 1975 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 18

Author index

A

ABRAMS, W. B. (*See* Azarnoff et al.), 650
ACCHIARDO, S. R. (*See* Skoutakis et al.), 200
ACHONG, M. R., PIAFSKY, K. M., AND OGILVIE, R. I. Comparison of cardiac effects of timolol and propranolol, 278
ADLER, D. S., MARTIN, E., GAMBERTOGLIO, J. G., TOZER, T. N., AND SPIRE, J.-P. Hemodialysis of phenytoin in a uremic patient, 65
ALBERT, J.-M. (*See* Cooper et al.), 325
ALLEN, L. M. (*See* Creaven and Allen), 221, 227
ALVÁN, G., ORME, M., BERTILSSON, L., EKSTRAND R., AND PALMÉR, L. Pharmacokinetics of indomethacin, 364
AMERSON, E. (*See* Cook et al.), 742
AMSTERDAM, E. A. (*See* Miller et al.), 598
ANDRES, R. (*See* Vestal et al.), 425
ARNOLD, J. D. (*See* Goldberg et al.), 643
ARONOW, W. S. (*See* Prakash et al.), 90
ATKINSON, A. J., JR., FINKEL, M. J., BURNS, J. J., HITCHINGS, G. H., KEMP, B. A., AND DE DENNIS, S. R. K., 659
—. (*See* Collinsworth et al.), 59
—. (*See* Strong et al.), 613
AVERY, D. H. (*See* Noyes et al.), 84
AZARNOFF, D. L., ABRAMS, W. B., CUTTNER, J., HEWITT, W. L., AND HAILMAN, H. F. Panel 3: Phase III investigations, 650

B

BELLVILLE, J. W. (*See* Gasser and Bellville), 175
—. (*See* Gasser et al.), 170
BENOWITZ, N. L., AND JONES, R. T. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion, 287
BERGER, F. M. Depression and antidepressant drugs, 241 (Commentary)
BERLIN, C. M., STACKMAN, J. M., AND VESELL, E. S. Quinine-induced alterations in drug disposition, 670
BERTILSSON, L. (*See* Alván et al.), 364
BERTRAND, M. (*See* Cooper et al.), 325
BESSELAAR, G. H. (*See* Goldberg et al.), 643
BIGGS, J. T. (*See* Spiker et al.), 539
BIRKETT, D. J. (*See* Pond et al.), 191
BIXLER, E. O. (*See* Kales et al.), 356
BLACK, M. (*See* Mitchell et al.), 70
BLACKER, H. M. (*See* Kostenbauder et al.), 449
BLACKWELL, B., STOLLEY, P. D., BUNCHER, R., KLIMT, C. R., TEMPLE, R., VENN, D., AND WARDELL, W. M. Panel 4: Phase IV investigations, 653
BLANCHARD, J. F. (*See* Thebault et al.), 485
BLATRIX, C. E. (*See* Thebault et al.), 485
BODEY, G. P. (*See* Rodriguez et al.), 462
BOLES, M. (*See* O'Malley et al.), 581
BRANNICK, L. J. (*See* Vukovich et al.), 215
BREIMER, D. D., ZILLY, W., AND RICHTER, E. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery, 433
BRESSLER, R. (*See* Carter et al.), 700
—. (*See* Nugent et al.), 338
BRIGGS, W. A., LOWENTHAL, D. T., CIRKSENA, W. J., PRICE, W. E., GIBSON, T. P., AND FLAMENBAUM, W. Propranolol in hypertensive dialysis patients: Efficacy and compliance, 606
—. (*See* Øie et al.), 680
BROCK, J. T. (*See* Cereghino et al.), 733
BRUNK, S. F. (*See* Noyes et al.), 84
BUNCHER, R. (*See* Blackwell et al.), 653
BURNS, J. J. (*See* Atkinson, et al.), 659
Burr, M. L., 238 (Correspondence)

C

CAHAN, D. H. (*See* Murphy et al.), 587
CALNE, D. B. (*See* Teychenne et al.), 273
CANTER, A. (*See* Noyes et al.), 84
CARR, E. A. (*See* Hollister et al.), 647
CARTER, D. E., BRESSLER, R., HUGHES, M. R., HAUSSLER, M. R., CHRISTIAN, C. D., AND HEINE, M. W. Effect of oral contraceptives on plasma clearance, 700
CARUSO, F. S. (*See* Dobkin et al.), 547
CASEY, J. H. (*See* Rodriguez et al.), 462
CEREGHINO, J. J., BROCK, J. T., VAN METER, J. C., PENRY, J. K., SMITH, L. D., AND WHITE, B. G. The efficacy of carbamazepine combinations in epilepsy, 733
CHANG, S. S. (*See* Spiker et al.), 539

July, pp. 1-132; August, pp. 133-240; September, pp. 241-374; October, pp. 375-506; November, part 1, pp. 507-628, part 2, pp. 629-662; December, pp. 663-784.

CHANG, Y.-H. (*See* Wiseman et al.), 441
CHRISTENSEN, C. N. (*See* Mirkin et al.), 657
CHRISTIAN, C. D. (*See* Carter el al.), 700
CIRKSENA, W. J. (*See* Briggs et al.), 606
CLARK, E. L. (*See* Rickels et al.), 315
COHEN, B. H. (*See* Vestal et al.), 425
COHEN, L. (*See* Dempsey et al.), 104
COHEN, S. N. (*See* Mirkin et al.), 657
COHN, H. D. (*See* Hollister et al.), 647
COHN, S. (*See* Turner and Cohn), 405
COLLINSWORTH, K. A., STRONG, J. M., ATKINSON, A. J., JR., WINKLE, R. A., PERLROTH, F., AND HARRISON, D. C. Pharmacokinetics and metabolism of lidocaine in patients with renal failure, 59
COOK, C. E., AMERSON, E., POOLE, W. K., LESSER, P., AND O'TUAMA, L. Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay, 742
—. (*See* Pruitt et al.), 112
COOPER, S. F., DUGAL, R., ALBERT, J.-M., AND BERTRAND, M. Penfluridol steady-state kinetics in psychiatric patients, 325
COTHAM, R. H., AND SHAND, D. Spuriously low plasma propranolol concentrations resulting from blood collection methods, 535
CRAIG, W. A. (*See* Welling et al.), 45
CREAVEN, P. J., AND ALLEN, L. M. EPEG, a new antineoplastic epipodophyllotoxin, 221
— AND —. PTG, a new antineoplastic epipodophyllotoxin, 227
CROUT, J. R. Clinical trials of drugs from the viewpoint of the Food and Drug Administration, 634
—. (*See* Hollister et al.), 647
CUTTNER, J. (*See* Azarnoff et al.), 650

D

DALTON, W. S., MARTZ, R., LEMBERGER, L., RODDA, B. E., AND FORNEY, R. B. Effects of marihuana combined with secobarbital, 298
DANON, A. (*See* Seyberth et al.), 521
DAS, K. J., AND EASTWOOD, M. A. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease, 514
DAVIDOV, M. E. (*See* Lee et al.), 154
DAYTON, P. G. (*See* O'Malley et al.), 581
—. (*See* Pruitt et al.), 112
DEANGELIS, R. L. (*See* Welch et al.), 249
DE DENNIS, S. R. K. (*See* Atkinson et al.), 659
DEMPSEY, R., MORGAN, J., AND COHEN, L. Reduction of enzyme efflux from skeletal muscle by diethylstilbestrol, 104
DITZLER, C. A. (*See* Duggan et al.), 205
—. (*See* Hare et al.), 330
DOBKIN, A. B., EAMKAOW, S., AND CARUSO, F. S. Butorphanol and pentazocine in patients with severe postoperative pain, 547
DOMINO, E. F. (*See* Sagalés et al.), 727
DONE, A. K. (*See* Mirkin et al.), 657
DUGAL, R. (*See* Cooper et al.), 325
DUGGAN, D. E., YEH, K. C., MATALIA, N., DITZLER, C. A., AND MCMAHON, F. G. Bioavailability of oral dexamethasone, 205
—. (*See* Hare et al.), 330
DUTCHER, J. S. (*See* Strong et al.), 613
DVORCHIK, B. H. (*See* Vesell et al.), 259

E

EAMKAOW, S. (*See* Dobkin et al.), 547
EASTWOOD, M. A. (*See* Das and Eastwood), 514
EKSTRAND, R. (*See* Alván et al.), 364
ELWOOD, C. M. (*See* Koup et al.), 9
EMBRO, W. J. (*See* Munson et al.), 687
ERILL, S. (*See* Sagalés et al.), 727

F

FALK, K. J. (*See* Wilson et al.), 165
FALKNER, F. (*See* Walter et al.), 571
FARMER, T. W. (*See* Welch et al.), 249
FEINSTEIN, A. R. Clinical biostatistics
XXXIII. On teaching statistics to medical students, 121
XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size, 491
FILLOUX, B. (*See* Guignard et al.), 401
FINDLEY, L. J. (*See* Teychenne et al.), 273
FINKEL, M. J. (*See* Atkinson et al.), 659
FINNERTY, F. A., JR. (*See* Lee et al.), 154
FISEROVA-BERGEROVA, V. (*See* Munson et al.), 687
FLAMENBAUM, W. (*See* Briggs et al.), 606
FORNEY, R. B. (*See* Dalton et al.), 298
FOSTER, T. S. (*See* Kostenbauder et al.), 449
FRANCIOSA, J. A., AND FREIS, E. D. Normal cardiac output during beta blockade with timolol in hypertensive patients, 158
FREI, E., III. (*See* Muss et al.), 234
FREIREICH, E. J. (*See* Rodriguez et al.), 462
FREIS, E. D. (*See* Franciosa and Freis), 158
FRÖLICH, J. C. (*See* Seyberth et al.), 521

G

GAMBERTOGLIO, J. G. (*See* Adler et al.), 65
GARRETTSON, L. K. (*See* Levy et al.), 210
GASSER, J. C., AND BELLVILLE, J. W. Respiratory effects of nefopam, 175
—, KAUFMAN, R. D., AND BELLVILLE, J. W. Respiratory effects of lorazepam, pentobarbital, and pentazocine, 170
GIBALDI, M., AND GRUNDHOFER, B. Biopharmaceutic influences on the anticholinergic effects of propantheline, 457
GIBSON, T. P. (*See* Briggs et al.), 606
GILBERT, C. A. (*See* Velasco et al.), 145
GILLESPIE, H. K. (*See* Hollister and Gillespie), 80, 714

GINGRICH, R. L., JR. (*See* Rickels et al.), 315
GLENWRIGHT, P. A. (*See* Vesell et al.), 259
GOLDBERG, L. I., BESSELAAR, G. H., ARNOLD, J. D., LEMBERGER, L., MITCHELL, J. R., AND WHITSETT, T. L. Panel 1: Phase I investigations, 643
GOTTSCHALK, L. A. (*See* Prakash et al.), 90
GRAHAM, G. G. (*See* Pond et al.), 191
GRAM, L. F., AND OVERØ, K. F. First-pass metabolism of nortriptyline in man, 305
GRAY, D. R. (*See* Vera et al.), 623
GRIFFITH, J. D., NUTT, J. G., AND JASINSKI, D. R. A comparison of fenfluramine and amphetamine in man, 563
GRUNDHOFER, B. (*See* Gibaldi and Grundhofer), 457
GUIGNARD, J. P., FILLOUX, B., LAVOIE, J., PELET, J., AND TORRADO, A. Effect of intravenous diazepam on renal function, 401
GUPTA, N., SARKISSIAN, E., AND PAULUS, H. E. Correlation of plateau serum salicylate level with rate of salicylate metabolism, 350

H

HAHN, R. G. (*See* Moertel et al.), 554
HAILMAN, H. F. (*See* Azarnoff et al.), 650
HANIN, I. (*See* Mallinger et al.), 467
HARE, L. E., YEH, K. C., DITZLER, C. A., MCMAHON, F. G., AND DUGGAN, D. E. Bioavailability of dexamethasone. II. Dexamethasone phosphate, 330
HARRISON, D. C. (*See* Collinsworth et al.), 59
HARRISON, I. (*See* Ramsay et al.), 391
HARTER, K. W. (*See* Vera et al.), 623
HATCH, F. E. (*See* Skoutakis et al.), 200
HAUSSLER, M. R. (*See* Carter et al.), 700
HEIMBERG, M. (*See* Seyberth et al.), 521
HEINE, M. W. (*See* Carter et al.), 700
HEWITT, W. L. (*See* Azarnoff et al.), 650
HITCHINGS, G. H. (*See* Atkinson et al.), 659
HOBBS, D. C. (*See* Wiseman et al.), 441
HOFMANN, L. M., POLK, R. C., AND MAIBACH, H. I. Renal clearance of canrenoate in normal man, 748
HOLADAY, D. A. (*See* Munson et al.), 687
HOLLISTER, L. E., AND GILLESPIE, H. K. Action of delta-9-tetrahydrocannabinol, 714
— AND —. Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol, 80
—, MARTZ, B. L., CARR, E. A., COHN, H. D., CROUT, J. R., AND LEVINE, J. Panel 2: Phase II investigations, 647
HOLSINGER, J. W., JR., AND MISCIA, V. F. Effect of acidosis on patients with myocardial ischemia, 594
HØWIE, V. M. (*See* Mirkin et al.), 657
HUGHES, M. R. (*See* Carter et al.), 700
HULON, W. C. (*See* Kostenbauder et al.), 449

I

INABA, T., AND KALOW, W. Salivary excretion of amobarbital in man, 558
INTURRISI, C. E. (*See* Kaiko and Inturrisi), 96
ISRAILI, Z. H. (*See* O'Malley et al.), 581

J

JANZEN, D. A. (*See* Vera et al.), 623
JASINSKI, D. R. (*See* Griffith et al.), 563
JOBERT, P., AND LASAGNA, L. Patient package inserts. I. Nature, notions, and needs, 507 (Commentary)
JOLLOW, D. J. (*See* Mitchell et al.), 70
JONES, R. T. (*See* Benowitz and Jones), 287
JOUBERT, P., KROENING, B., AND WEINTRAUB, M. Serial serum digoxin concentrations and quantitative electrocardiographic changes, 757
— AND LASAGNA, L. Patient package inserts. II. Toward a rational patient package insert, 663 (Commentary)
JUSKO, W. J. (*See* Koup et al.), 9
—. (*See* Lewis and Jusko), 475

K

KAIKO, R. F., AND INTURRISI, C. E. Disposition of acetylmethadol in relation to pharmacologic action, 96
KALES, A., KALES, J. D., BIXLER, E. O., AND SCHARF, M. B. Effectiveness of hypnotic drugs with prolonged use: Flurazepam and pentobarbital, 356
KALES, J. D. (*See* Kales et al.), 356
KALOW, W. (*See* Inaba and Kalow), 558
KAUFMAN, R. D. (*See* Gasser et al.), 170
KAYAN, S. (*See* Nugent et al.), 338
KEISER, H. R. (*See* Mitchell et al.), 70
KEMP, B. A. (*See* Atkinson et al.), 659
KENNEDY, T. (*See* Seyberth et al.), 521
KHANDELWAL, J. (*See* Walter et al.), 571
KINKEL, A. W. (*See* Kostenbauder et al.), 449
KLIMT, C. R. (*See* Blackwell et al.), 653
KOHLI, R. K. (*See* Koup et al.), 9
KOSTENBAUDER, H. B., RAPP, R. P., MCGOVREN, J. P., FOSTER, T. S., PERRIER, D. G., BLACKER, H. M., HULON, W. C., AND KINKEL, A. W. Bioavailability and single-dose pharmacokinetics of intramuscular phenytoin, 449
KOUP, J. R., JUSKO, W. J., ELWOOD, C. M., AND KOHLI, R. K. Digoxin pharmacokinetics: Role of renal failure in dosage regimen design, 9
KROENING, B. (*See* Joubert et al.), 757
KUNIN, C. M. (*See* Welling et al.), 45
KUPFER, D. J. (*See* Mallinger et al.), 467

L

LABELLE, J. L. (*See* Wilson et al.), 165
LASAGNA, L. Clinical trials of drugs from the viewpoint of the academic investigator (a satire), 629

—. Reflections in a crystal ball, 1 (Commentary)
—. (*See* Joubert and Lasagna), 507, 663 (Commentary)
LASKA, E. (*See* Sunshine and Laska), 530
LAVERTY, W. (*See* Prakash et al.), 90
LAVOIE, J. (*See* Guignard et al.), 401
LEE, W.-K. (*See* Strong et al.), 613
LEE, W. R., MROCZEK, W. J., DAVIDOV, M. E., AND FINNERTY, F. A., JR. Nonemergency use of slow infusions of diazoxide, 154
LEENEN, F. H. H., REDMOND, D. P., AND MCDONALD, R. H., JR. Alpha and beta adrenergic–induced renin release in man, 31
LEMBERGER, L., AND ROWE, H. Clinical pharmacology of nabilone, a cannabinol derivative, 720
—. (*See* Dalton et al.), 298
—. (*See* Goldberg et al.), 643
LESSER, P. (*See* Cook et al.), 742
LEVINE, J. (*See* Hollister et al.), 647
LEVY, G., PROCKNAL, J. A., AND GARRETTSON, L. K. Distribution of salicylate between neonatal and maternal serum at diffusion equilibrium, 210
—. (*See* Øie et al.), 680
LEWIS, G. P., AND JUSKO, W. J. Pharmacokinetics of ampicillin in cirrhosis, 475
LEWIS, P. J. (*See* Teychenne et al.), 273
LINDENBAUM, J. (*See* Mallis et al.), 761
LOCKHART, J. D. (*See* Mirkin et al.), 657
LOKICH, J. J. (*See* Muss et al.), 234
LOWENTHAL, D. T. (*See* Briggs et al.), 606
—. (*See* Øie et al.), 680
LUNA, M. (*See* Rodriguez et al.), 462

M

MAIBACH, H. I. (*See* Hofmann et al.), 748
MALAGODI, M. H. (*See* Munson et al.), 687
MALLINGER, A. G., KUPFER, D. J., POUST, R. J., AND HANIN, I. In vitro and in vivo transport of lithium by human erythrocytes, 467
MALLIS, G. I., SCHMIDT, D. H., AND LINDENBAUM, J. Superior bioavailability of digoxin solution in capsules, 761
MARTIN, E. (*See* Adler et al.), 65
MARTZ, B. L. (*See* Hollister et al.), 647
MARTZ, R. (*See* Dalton et al.), 298
MASON, D. T. (*See* Miller et al.), 598
—. (*See* Vera et al.), 623
MASSUMI, R. A. (*See* Vera et al.), 623
MATALIA, N. (*See* Duggan et al.), 205
MCALLISTER, R. G. (*See* Shand et al.), 139
MCCREDIE, K. B. (*See* Rodriguez et al.), 462
MCDEVITT, D. G., AND SHAND, D. G. Plasma concentrations and the time-course of beta blockade due to propranolol, 708
MCDONALD, R. H., JR. (*See* Leenen et al.), 31
MCGOVREN, J. P. (*See* Kostenbauder et al.), 449
MCMAHON, F. G. Europeanization of American drug discovery, 375 (Editorial)
—. (*See* Duggan et al.), 205
—. (*See* Hare et al.), 330
MCNAY, J. L. (*See* O'Malley and McNay), 39
—. (*See* O'Malley et al.), 53, 581
—. (*See* Velasco et al.), 145
MEYER, M. C. (*See* Skoutakis et al.), 200
MILLER, R. R., OLSON, H. G., PRATT, C. M., AMSTERDAM, E. A., AND MASON, D. T. Efficacy of beta adrenergic blockade in coronary heart disease: Propranolol in angina pectoris, 598
MINOW, R. A. (*See* Rodriguez et al.), 462
MIRKIN, B. L., DONE, A. K., CHRISTENSEN, C. N., COHEN, S. N., HOWIE, V. M., AND LOCKHART, J. D. Panel on pediatric trials, 657
MISCIA, V. F. (*See* Holsinger and Miscia), 594
MITCHELL, J. R., THORGEIRSSON, U. P., BLACK, M., TIMBRELL, J. A., SNODGRASS, W. R., POTTER, W. Z., JOLLOW, D. J., AND KEISER, H. R. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites, 70
—. (*See* Goldberg et al.), 643
MOERTEL, C. G., SCHUTT, A. J., HAHN, R. G., AND O'FALLON, J. R. Oral benzquinamide in the treatment of nausea and vomiting, 554
MOLINOFF, P. B. (*See* Murphy et al.), 587
MORGAN, J. (*See* Dempsey et al.), 104
MORRIS, R. J. (*See* Rickels et al.), 315
MROCZEK, W. J. (*See* Lee et al.), 154
MULÉ, S. (*See* Verebely et al.), 180
MUNSON, E. S., MALAGODI, M. H., SHIELDS, R. P., THAM, M. K., FISEROVA-BERGEROVA, V., HOLADAY, D. A., PERRY, J. C., AND EMBRO, W. J. Fluroxene toxicity induced by phenobarbital, 687
MURPHY, D. L., CAHAN, D. H., AND MOLINOFF, P. B. Occurrence, transport, and storage of octopamine in human thrombocytes, 587
MUSS, H. B., LOKICH, J. J., AND FREI, E., III. 5-Fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer, 234

N

NEISS, E. S. (*See* Vukovich et al.), 215
NGUYEN, K. B. (*See* Wilson et al.), 165
NIES, A. S. (*See* Shand et al.), 139
—. (*See* Walter et al.), 571
NORRIS, A. H. (*See* Vestal et al.), 425
NOYES, R., JR., BRUNK, S. F., AVERY, D. H., AND CANTER, A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine, 84
NUGENT, C. A., BRESSLER, R., KAYAN, S., AND WORRALL, P. Suppression of cortisol by a progestational steroid, melengestrol, 338
NUTT, J. G. (*See* Griffith et al.), 563

O

Oates, J. A. (*See* Seyberth et al.), 521
—. (*See* Shand et al.), 139
Oelz, O. (*See* Seyberth et al.), 521
O'Fallon, J. R. (*See* Moertel et al.), 554
Ogilvie, R. I. (*See* Achong et al.), 278
Øie, S., Lowenthal, D. T., Briggs, W. A., and Levy, G. Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients, 680
Olson, H. G. (*See* Miller et al.), 598
O'Malley, K. O., and McNay, J. L. A method for achieving blood pressure control expeditiously with oral minoxidil, 39
—, Segal, J. L., Israili, Z. H., Boles, M., McNay, J. L., and Dayton, P. G. Duration of hydralazine action in hypertension, 581
—, Velasco, M., Pruitt, A., and McNay, J. L. Decreased plasma protein binding of diazoxide in uremia, 53
Orme, M. (*See* Alván et al.), 364
O'Tuama, L. (*See* Cook et al.), 742
Overø, K. F. (*See* Gram and Overø), 305

P

Palmér, L. (*See* Alván et al.), 364
Panak, E. A. (*See* Thebault et al.), 485
Passananti, G. T. (*See* Vesell et al.), 259
Patterson, J. H. (*See* Pruitt et al.), 112
Paulus, H. E. (*See* Gupta et al.), 350
Pelet, J. (*See* Guignard et al.), 401
Peltier, H. C. Clinical trials of drugs from the viewpoint of the pharmaceutical industry, 637
Penry, J. K. (*See* Cereghino et al.), 733
Perloff, M. M. (*See* Rickels et al.), 315
Perlroth, F. (*See* Collinsworth et al.), 59
Perrier, D. G. (*See* Kostenbauder et al.), 449
Perry, J. C. (*See* Munson et al.), 687
Piafsky, K. M. (*See* Achong et al.), 278
Polk, R. C. (*See* Hofmann et al.), 748
Pond, S. M., Graham, G. G., Birkett, D. J., and Wade, D. N. Effects of tricyclic antidepressants on drug metabolism, 191
Poole, W. K. (*See* Cook et al.), 742
Potter, W. Z. (*See* Mitchell et al.), 70
Poust, R. I. (*See* Mallinger et al.), 467
Prakash, R., Aronow, W. S., Warren, M., Laverty, W., and Gottschalk, L. A. Effects of marihuana and placebo marihuana smoking on hemodynamics in coronary disease, 90
Prasad, K. Electrophysiologic effects of glucagon on human cardiac muscle, 22
Pratt, C. M. (*See* Miller et al.), 598
Price, W. E. (*See* Briggs et al.), 606
Procknal, J. A. (*See* Levy et al.), 210
Pruitt, A. (*See* O'Malley et al.), 53
Pruitt, A. W., Zwiren, G. T., Patterson, J. H., Dayton, P. G., Cook, C. E., and Wall, M. E. A complex pattern of disposition of phenytoin in severe intoxication, 112

R

Ramsay, L., Harrison, I., Shelton, J., and Tidd, M. Relative potency of prorenoate and spironolactone in normal man, 391
Rapp, R. P. (*See* Kostenbauder et al.), 449
Recker, R. R. Effect of hydrochlorothiazide on phosphorus during treatment with diphosphonate, 345
Redmond, D. P. (*See* Leenen et al.), 31
Resnick, R. (*See* Verebely et al.), 180
Richter, E. (*See* Breimer et al.), 433
Rickels, K., Gingrich, R. L., Jr., Morris, R. J., Rosenfeld, H., Perloff, M. M., Clark, E. L., and Schilling, A. Triazolam in insomniac family practice patients, 315
Rodda, B. E. (*See* Dalton et al.), 298
Rodriguez, V., Bodey, G. P., McCredie, K. B., Freireich, E. J., Minow, R. A., Casey, J. H., and Luna, M. Combination 6-mercaptopurine-adriamycin in refractory adult acute leukemia, 462
Rosenfeld, H. (*See* Rickels et al.), 315
Rowe, H. (*See* Lemberger and Rowe), 720
Rutledge, C. O. (*See* Velasco et al.), 145
Ruwitch, J. F., Jr. (*See* Spiker et al.), 539

S

Sagalés, T., Erill, S., and Domino, E. F. Effects of repeated doses of scopolamine on the electroencephalographic stages of sleep in normal volunteers, 727
Sarkissian, E. (*See* Gupta et al.), 350
Scharf, M. B. (*See* Kales et al.), 356
Schilling, A. (*See* Rickels et al.), 315
Schmidt, D. H. (*See* Mallis et al.), 761
Schutt, A. J. (*See* Moertel et al.), 554
Segal, J. L. (*See* O'Malley et al.), 581
Seyberth, H. W., Oelz, O., Kennedy, T., Sweetman, B. J., Danon, A., Frölich, J. C., Heimberg, M., and Oates, J. A. Increased arachidonate in lipids after administration to man: Effects on prostaglandin biosynthesis, 521
Shand, D. (*See* Cotham and Shand), 535
Shand, D. G., Nies, A. S., McAllister, R. G., and Oates, J. A. A loading-maintenance regimen for more rapid initiation of the effect of guanethidine, 139
—. (*See* McDevitt and Shand), 708
—. (*See* Wilkinson and Shand), 377 (Commentary)
Shelton, J. (*See* Ramsay et al.), 391
Shields, R. P. (*See* Munson et al.), 687
Shively, C. A., and Vesell, E. S. Temporal variations in acetaminophen and phenacetin half-life in man, 413
Shock, N. W. (*See* Vestal et al.), 425
Sicé, J. Major drug-prescribing patterns in general hospitals, 133 (Commentary)
Skoutakis, V. A., Acchiardo, S. R., Meyer, M. C., and Hatch, F. E. Folic acid dosage for chronic hemodialysis patients, 200

SMITH, L. D. (*See* Cereghino et al.), 733
SNODGRASS, W. R. (*See* Mitchell et al.), 70
SPIKER, D. G., WEISS, A. N., CHANG, S. S., RUWITCH, J. F., JR., AND BIGGS, J. T. Tricyclic antidepressant overdose: Clinical presentation and plasma levels, 539
SPIRE, J.-P. (*See* Adler et al.), 65
STACKMAN, J. M. (*See* Berlin et al.), 670
STOLLEY, P. D. (*See* Blackwell et al.), 653
STRONG, J. M., DUTCHER, J. S., LEE, W.-K., AND ATKINSON, A. J., JR. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method, 613
—. (*See* Collinsworth et al.), 59
SUGERMAN, A. A. (*See* Vukovich et al.), 215
SUNSHINE, A., AND LASKA, E. Nefopam and morphine in man, 530
SWEETMAN, B. J. (*See* Seyberth et al.), 521

T

TEMPLE, R. (*See* Blackwell et al.), 653
TEYCHENNE, P. F., CALNE, D. B., LEWIS, P. J., AND FINDLEY, L. J. Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase, 273
THAM, M. K. (*See* Munson et al.), 687
THEBAULT, J. J., BLATRIX, C. E., BLANCHARD, J. F., AND PANAK, E. A. Effects of ticlopidine, a new platelet aggregation inhibitor in man, 485
THORGEIRSSON, U. P. (*See* Mitchell et al.), 70
TIDD, M. (*See* Ramsay et al.), 391
TIMBRELL, J. A. (*See* Mitchell et al.), 70
TOBIN, J. D. (*See* Vestal et al.), 425
TORRADO, A. (*See* Guignard et al.), 401
TOZER, T. N. (*See* Adler et al.), 65
TURNER, W. J., AND COHN, S. Total body potassium and 24-hour creatinine excretion in healthy males, 405

V

VAN METER, J. C. (*See* Cereghino et al.), 733
VELASCO, M., GILBERT, C. A., RUTLEDGE, C. O., AND MCNAY, J. L. Antihypertensive effect of a dopamine beta hydroxylase inhibitor, bupicomide: A comparison with hydralazine, 145
—. (*See* O'Malley et al.), 53
VENN, D. (*See* Blackwell et al.), 653
VERA, Z., GRAY, D. R., HARTER, K. W., JANZEN, D. A., MASSUMI, R. A., AND MASON, D. T. Electrophysiologic properties of perhexiline, 623
VEREBELY, K., VOLAVKA, J., MULÉ, S., AND RESNICK, R. Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment, 180
VESELL, E. S., PASSANANTI, G. T., GLENWRIGHT, P A., AND DVORCHIK, B. H. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine, 259
—. (*See* Berlin et al.), 670
—. (*See* Shively and Vesell), 413
VESTAL, R. E., NORRIS, A. H., TOBIN, J. D., COHEN, B. H., SHOCK, N. W., AND ANDRES, R. Antipyrine metabolism in man: Influence of age, alcohol, caffeine, and smoking, 425
VOLAVKA, J. (*See* Verebely et al.), 180
VUKOVICH, R. A., BRANNICK, L. J., SUGERMAN, A. A., AND NEISS, E. S. Sex differences in the intramuscular absorption and bioavailability of cephradine, 215

W

WADE, D. N. (*See* Pond et al.), 191
WALL, M. E. (*See* Pruitt et al.), 112
WALTER, I. E., KHANDELWAL, J., FALKNER, F., AND NIES, A. S. The relationship of plasma guanethidine levels to adrenergic blockade, 571
WARDELL, W. M. (*See* Blackwell et al.), 653
WARREN, M. (*See* Prakash et al.), 90
WEINTRAUB, M. (*See* Joubert et al.), 757
WEISS, A. N. (*See* Spiker et al.), 539
WELCH, R. M., DEANGELIS, R. L., WINGFIELD, M., AND FARMER, T. W. Elimination of antipyrine from saliva as a measure of metabolism in man, 249
WELLING, P. G., CRAIG, W. A., AND KUNIN, C. M. Prediction of drug dosage in patients with renal failure using data derived from normal subjects, 45
WHITE, B. G. (*See* Cereghino et al.), 733
WHITSETT, T. L. (*See* Goldberg et al.), 643
WILKINSON, G. R., AND SHAND, D. G. A physiological approach to hepatic drug clearance, 377 (Commentary)
WILSON, T. W., FALK, K. J., LABELLE, J. L., AND NGUYEN, K. B. Effect of dosage regimen on natriuretic response to furosemide, 165
WINGFIELD, M. (*See* Welch et al.), 249
WINKLE, R. A. (*See* Collinsworth et al.), 59
WISEMAN, E. H., CHANG, Y.-H., AND HOBBS, D. C. Interaction of sudoxicam and aspirin in animals and man, 441
WORRALL, P. (*See* Nugent et al.), 338

Y

YEH, K. C. (*See* Duggan et al.), 205
—. (*See* Hare et al.), 330

Z

ZILLY, W. (*See* Breimer et al.), 433
ZWIREN, G. T. (*See* Pruitt et al.), 112

Subject index

A

Academic investigator, clinical trials of drugs from viewpoint of (satire) (Lasagna), 629
Acetaminophen elimination by anephric patients, effect of hemodialysis on kinetics of (Øie et al.), 680
and phenacetin half-life in man, temporal variations in (Shively and Vesell), 413
Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease (Das and Eastwood), 514
Acetylhydrazine, high concentrations of, in rapid acetylators (Mitchell et al.), 70
Acetylmethadol, disposition of, in relation to pharmacologic action (Kaiko and Inturrisi), 96
Acid, folic, dosage, for chronic hemodialysis patients (Skoutakis et al.), 200
Acidosis, effect of, on patients with myocardial ischemia (Holsinger and Miscia), 594
Adenosine diphosphate–induced platelet aggregation, inhibition of, with ticlopidine (Thebault et al.), 485
Adrenergic blockade, beta, efficacy of, in coronary heart disease, propranolol in angina pectoris (Miller et al.), 598
relationship of plasma guanethidine levels to (Walter et al.), 571
induced renin release in man, alpha and beta (Leenen et al.), 31
Adrenocorticosteroids involved in circadian changes in rate of drug metabolism (Shively and Vesell), 413
Adriamycin, 6-mercaptopurine-, combination, in refractory adult acute leukemia (Rodriquez et al.), 462
Age, alcohol, caffeine, and smoking, antipyrine metabolism in man, influence of (Vestal et al.), 425
Aggregation inhibitor in man, new, effects of ticlopidine (Thebault et al.), 485
Alcohol, age, caffeine, and smoking, influence of, antipyrine metabolism in man (Vestal et al.), 425
American drug discovery, Europeanization of (McMahon), 375 (Editorial)
Amino acid decarboxylase, L-aromatic, interactions of levodopa with inhibitors of monoamine oxidase and (Teychenne et al.), 273
Aminopyrine, antipyrine, and phenacetin, studies on disposition of, using plasma, saliva, and urine (Vesell et al.), 259
Amobarbital, salivary excretion of, in man (Inaba and Kalow), 558
Amphetamine, fenfluramine and, comparison of, in man (Griffith et al.), 563
Ampicillin in cirrhosis, pharmacokinetics of (Lewis and Jusko), 475
Analgesic, new chemically unrelated, nefopam (Sunshine and Laska), 530
postoperative, butorphanol compared to pentazocine (Dobkin et al.), 547
properties of delta-9-tetrahydrocannabinol and codeine (Noyes et al.), 84
respiratory effects of nefopam as, (Gasser and Bellville), 175
Anephric patients, effect of hemodialysis on kinetics of acetaminophen elimination by (Øie et al.), 680
Anesthesia, fluroxene, tolerated by rhesus monkeys, prior treatment with phenobarbital cause of intensified toxicity (Munson et al.), 687
Angina pectoris, propranolol in (Miller et al.), 598
relief of, by acceleration of oxygen transport by blood (Holsinger and Miscia), 594
Animals and man, interaction of sudoxicam and aspirin in (Wiseman et al.), 441
Announcements, 132, 239, 374
Antipyrine, aminopyrine, and phenacetin, studies on disposition of, using plasma, saliva, and urine (Vesell et al.), 259
disposition, effects of quinine on (Berlin et al.), 670
elimination of, from saliva as measure of metabolism in man (Welch et al.), 249
metabolism in man, influence of age, alcohol, caffeine, and smoking (Vestal et al.), 425
and phenybutazone, attempts to correlate marihuana effects after THC and 11-OH-THC in rapid and slow hydroxylators, as determined with (Hollister and Gillespie), 714
and vitamin D_3, half-life of altered by oral steroid contraceptive therapy (Carter et al.), 700
Arabinoside, cytosine, 5-fluorouracil with, in metastatic gastrointestinal cancer (Muss et al.), 234
Arachidonate, increased, in lipids after administration to man, effects on prostaglandin biosynthesis (Seyberth et al.), 521
Arthritis, rheumatoid, correlation of plateau serum salicylate level with rate of salicylate metabolism in (Gupta et al.), 350
Ascorbic acid, factors influencing metabolic availability of (Burr), 238 (Correspondence)
Aspirin, sudoxicam and, interaction of, in animals and man (Wiseman et al.), 441

July, pp. 1-132; August, pp. 133-240; September, pp. 241-374; October, pp. 375-506; November, part 1, pp. 507-628, part 2, pp. 629-662; December, pp. 663-784.

B

Benzquinamide, oral, in treatment of nausea and vomiting (Moertel et al.), 554
Beta adrenergic blockade, efficacy of, in coronary heart disease, propranolol in angina pectoris (Miller et al.), 598
blockade, plasma concentrations and time-course of, due to propranolol (McDevitt and Shand), 708
Bioavailability, absolute, in man of N-acetylprocainamide determined by novel stable isotope method (Strong et al.), 613
of cephradine, intramuscular absorption and, sex differences in (Vukovich et al.), 215
of dexamethasone; dexamethasone phosphate (Hare et al.), 330
of oral dexamethasone (Duggan et al.), 205
and single-dose pharmacokinetics of intramuscular phenytoin (Kostenbauder et al.), 449
superior, of digoxin solution in capsules (Mallis et al.), 761
Biopharmaceutic influences on anticholinergic effects of propantheline (Gibaldi and Grundhofer), 457
Biostatistics, clinical (Feinstein)
XXXIII. On teaching statistics to medical students, 121
XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size, 491
medical, proposal for core curriculum in, 127
Biosynthesis, prostaglandin, effects of arachidonate on (Seyberth et al.), 521
Blood collection methods, spuriously low plasma propranolol concentrations resulting from (Cotham and Shand), 535
pressure control, method for achieving expeditiously with oral minoxidil (O'Malley et al.), 39
lowering after oral delta-9-tetrahydrocannabinol (Benowitz and Jones), 287
moderate fall in, in administration of diazoxide (Lee et al.), 154
standard increase in heart rate and, in marihuana and placebo marihuana smokers (Prakash et al.), 90
Books received, 240, 506
Bupicomide, antihypertensive effect of, comparison with hydralazine (Velasco et al.), 145
Butorphanol and pentazocine in patients with severe postoperative pain (Dobkin et al.), 547

C

Caffeine, age, alcohol, and smoking, influence of; antipyrine metabolism in man (Vestal et al.), 425
Cancer, metastatic gastrointestinal, 5-fluorouracil with cytosine arabinoside in (Muss et al.), 234
patients, THC associated with pain relief in (Noyes et al.), 84
Cannabinol and cannabidiol; interactions in man of delta-9-tetrahydrocannabinol (Hollister and Gillespie), 80
derivative, nabilone, clinical pharmacology of (Lemberger and Rowe), 720
Canrenoate, renal clearance of, in normal man (Hofmann et al.), 748
Carbamazepine combinations, efficacy of, in epilepsy (Cereghino et al.), 733
Cardiac acceleration, nonemergency use of slow infusions of diazoxide and (Lee et al.), 154
effects of timolol and propranolol, comparison of (Achong et al.), 278
muscle, human, electrophysiologic effects of glucagon on (Prasad et al.), 22
nontoxicity, relative, of perhexiline as antiarrhythmic (Vera et al.), 623
output, normal, during beta blockade with timolol in hypertensive patients (Franciosa and Freis), 158
Cardiovascular and CNS effects demonstrated in nabilone (Lemberger and Rowe), 720
effects of prolonged delta-9-tetrahydrocannabinol ingestion (Benowitz and Jones), 287
Central nervous system effects, cardiovascular and, demonstrated in nabilone (Lemberger and Rowe), 720
Cephradine, intramuscular absorption and bioavailability of, sex differences in (Vukovich et al.), 215
Child, unusual aspects of severe intoxication of, with phenytoin (Pruitt et al.), 112
Circadian changes in rate of drug metabolism, adrenocorticosteroids involved in (Shively and Vesell), 413
Cirrhosis, pharmacokinetics of ampicillin in (Lewis and Jusko), 475
Clinical biostatistics (Feinstein)
XXXIII. On teaching statistics to medical students, 121
XXXIV. The other side of 'statistical significance': alpha, beta, delta, and the calculation of sample size, 491
trials of drugs from viewpoint of academic investigator (satire)(Lasagna), 629
of Food and Drug Administration (Crout), 634
of pharmaceutical industry (Peltier), 637
Codeine, analgesic properties of delta-9-tetrahydrocannabinol and (Noyes et al.), 84
Colitis, ulcerative, and Crohn's disease, acetylation polymorphism of sulfapyridine in patients with (Das and Eastwood), 514
Contraceptives, oral, effect of, on plasma clearance (Carter et al.), 700
Coronary disease, effects of marihuana and placebo marihuana smoking on hemodynamics in (Prakash et al.), 90
heart disease, efficacy of beta adrenergic blockade in (Miller et al.), 598

Cortisol, suppression of, by progestational steroid, melengestrol (Nugent et al.), 338
Creatinine excretion, 24-hour, total body potassium and, in healthy males (Turner and Cohn), 405
Crohn's disease, acetylation polymorphism of sulfapyridine in patients with (Das and Eastwood), 514
Cytosine arabinoside in metastatic gastrointestinal cancer, 5-fluorouracil with (Muss et al.), 234

D

Delta-9-tetrahydrocannabinol, action of (Hollister and Gillespie), 714
Depressant(s) overdose, tricyclic anti-, clinical presentation and plasma levels (Spiker et al.), 539
  tricyclic anti-, effects of, on drug metabolism (Pond et al.), 191
Depression and antidepressant drugs (Berger), 241 (Commentary)
Dexamethasone, bioavailability of; dexamethasone phosphate (Hare et al.), 330
  oral, bioavailability of (Duggan et al.), 205
Dialysis patients, hypertensive, propranolol in (Briggs et al.), 606
  phenytoin recovered by, in uremic patient (Adler et al.), 65
  prevention of losses of folate during, by administration of folic acid (Skoutakis et al.), 200
Diazepam, intravenous, effect of, on renal function (Guignard et al.), 401
Diazoxide, decreased plasma protein binding of, in uremia (O'Malley et al.), 53
  nonemergency use of slow infusions of (Lee et al.), 154
Dicumarol metabolism, changes in, associated with use of amitriptyline or nortriptyline (Pond et al.), 191
Diethylstilbestrol, reduction of enzyme efflux from skeletal muscle by (Dempsey et al.), 104
Digitalis intoxication, glucagon suitable for clinical use in (Prasad), 22
Digoxin concentrations, serial serum, and quantitative electrocardiographic changes (Joubert et al.), 757
  pharmacokinetics; role of renal failure in dosage regimen design (Koup et al.), 9
  solution in capsules, superior bioavailability of (Mallis et al.), 761
Diphosphonate, effect of hydrochlorothiazide on phosphorus during treatment with (Recker), 345
Diuresis and furosemide dosage (Wilson et al.), 165
Dog's heart, intact, lack of effect on conducting system of perhexiline (Vera et al.), 623
Dopamine beta hydroxylase inhibitor, bupicomide, antihypertensive effect of; comparison with hydralazine (Velasco et al.), 145
Dosage, drug, prediction of, in patients with renal failure using data derived from normal subjects (Welling et al.), 45
  regimen design, role of renal failure in; digoxin pharmacokinetics (Koup et al.), 9
  effect of, on natriuretic response to furosemide (Wilson et al.), 165
Drug(s) clearance, hepatic, physiological approach to (Wilkinson and Shand), 377 (Commentary)
  clinical trials of, from viewpoint of academic investigator (satire)(Lasagna), 629
    of Food and Drug Administration (Crout), 634
    of pharmaceutical industry (Peltier), 637
  disposition, quinine-induced alterations in (Berlin et al.), 670
  dosage, prediction of, in patients with renal failure using data derived from normal subjects (Welling et al.), 45
  metabolism, effects of tricyclic antidepressants on (Pond et al.), 191
  -prescribing patterns, major, in general hospitals (Sicé), 133 (Commentary)
  public service, and new uses for old drugs, panel on (Atkinson et al.), 659
Duchenne's muscular dystrophy, action of diethylstilbestrol in (Dempsey et al.), 104

E

Electrocardiographic changes, quantitative, serial serum digoxin concentrations and (Joubert et al.), 757
Electroencephalographic stages of sleep in normal volunteers, effects of repeated doses of scopolamine on (Sagalés et al.), 727
Electrophysiologic effects of glucagon on human cardiac muscle (Prasad et al.), 22
  properties of perhexiline (Vera et al.), 623
Enzyme efflux, reduction of, from skeletal muscle by diethylstibestrol (Dempsey et al.), 104
Epilepsy, efficacy of carbamazepine combinations in (Cereghino et al.), 733
Epipodophyllotoxin, antineoplastic, EPEG new (Creaven and Allen), 221
  PTG, new (Creaven and Allen), 227
Equilibrium, diffusion, distribution of salicylate between neonatal and maternal serum at (Levy et al.), 210
Erythrocytes, human, in vitro and in vivo transport of lithium by (Mallinger et al.), 467
Europeanization of American drug discovery (McMahon), 375 (Editorial)
Excretion studies, pharmacokinetic and, in acute and chronic treatment; methadone in man (Verebely et al.), 180

F

Fenfluramine and amphetamine in man, comparison of (Griffith et al.), 563

5-Fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer (Muss et al.), 234

Flurazepam and pentobarbital, effectiveness of hypnotic drugs with prolonged use (Kales et al.), 356

Fluroxene toxicity induced by phenobarbital (Munson et al.), 687

Folic acid dosage for chronic hemodialysis patients (Skoutakis et al.), 200

Food and Drug Administration, clinical trials of drugs from viewpoint of (Crout), 634

Furosemide, effect of dosage regimen on natriuretic response to (Wilson et al.), 165

G

Gastrointestinal cancer, metastatic, 5-fluorouracil with cytosine arabinoside in (Muss et al.), 234

Glucagon, electrophysiologic effects of, on human cardiac muscle (Prasad et al.), 22

Guanethidine levels, plasma, relationship of, to adrenergic blockade (Walter et al.), 571

loading-maintenance regimen for more rapid initiation of effect of (Shand et al.), 139

H

Heart disease, coronary, efficacy of beta adrenergic blockade in (Miller et al.), 598

Hemodialysis, effect of, on kinetics of acetaminophen elimination by anephric patients (Øie et al.), 680

major route of elimination of acetaminophen metabolites in anephric patients (Øie et al.), 680

patients, folic acid dosage for (Skoutakis et al.), 200

of phenytoin in uremic patient (Adler et al.), 65

Hepatic drug clearance, physiological approach to (Wilkinson and Shand), 377 (Commentary)

Hepatitis, acute, pharmacokinetics of hexobarbital in, and after apparent recovery (Breimer et al.), 433

isoniazid, increased incidence of, in rapid acetylators; possible relation to hydrazine metabolites (Mitchell et al.), 70

Hepatotoxic effects in adults with refractory acute leukemia treated with 6-mercaptopurine-adriamycin (Rodriguez et al.), 462

Hexobarbital, pharmacokinetics of, in acute hepatitis and after apparent recovery (Breimer et al.), 433

Hydralazine action, duration of, in hypertension (O'Malley et al.), 581

Hydralazine—cont'd

antihypertensive effect of, comparison with bupicomide (Velasco et al.), 145

Hydrazine metabolites, possible relation of increased incidence of isoniazid hepatitis in rapid acetylators to (Mitchell et al.), 70

Hydrochlorothiazide, effect of, on phosphorus during treatment with diphosphonate (Recker), 345

Hyperaldosteronism, absence of, little change in urinary electrolyte induced by canrenoate (Hofmann et al.), 748

Hypertension, duration of hydralazine action in (O'Malley et al.), 581

features of effects of minoxidil in (O'Malley and McNay), 39

Hypertensive dialysis patients, propranolol in, efficacy and compliance (Briggs et al.), 606

patients, guanethidine in (Shand et al.), 139

normal cardiac output during beta blockade with timolol in (Franciosa and Freis), 158

Hypnotic drugs, effectiveness of, with prolonged use; flurazepam and pentobarbital (Kales et al.), 356

I

Indomethacin, pharmacokinetics of (Alván et al.), 364

Insomniac(s), chronic, effectiveness of flurazepam and pentobarbital in (Kales et al.), 356

family practice patients, triazolam in (Rickels et al.), 315

Intoxication, severe, complex pattern of disposition of phenytoin in (Pruitt et al.), 112

Inulin and PAH clearances, decreases in, after intravenous diazepam (Guignard et al.), 401

Investigations, Phase I, in clinical trials of drugs (Goldberg et al.), 643

Phase II, in clinical trials of drugs (Hollister et al.), 647

Phase III, in clinical trials of drugs (Azarnoff et al.), 650

Phase IV, in clinical trials of drugs (Blackwell et al.), 653

Investigator, academic, clinical trials of drugs from viewpoint of (satire) (Lasagna), 629

Ischemia, myocardial, effect of acidosis on patients with (Holsinger and Miscia), 594

Isoniazid hepatitis, increased incidence of, in rapid acetylators; possible relation to hydrazine metabolites (Mitchell et al.), 70

Isoproterenol, comparison of timolol and propranolol as antagonist of chronotropic and ionotropic effects of (Achong et al.), 278

Isotope method, novel stable, absolute bioavailability in man of N-acetylprocainamide determined by (Strong et al.), 613

K

Kaliuresis, prorenoate more potent suppressor of than spironolactone (Ramsay et al.), 391

L

Leukemia, refractory adult acute, combination 6-mercaptopurine-adriamycin in (Rodriguez et al.), 462
Levodopa, interactions of, with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase (Teychenne et al.), 273
Lidocaine, pharmacokinetics and metabolism of, in patients with renal failure (Collinsworth et al.), 59
Lipids, increased arachidonate in, after administration to man, effects on prostaglandin biosynthesis (Seyberth et al.), 521
Lithium, in vitro and in vivo transport of, by human erythrocytes (Mallinger et al.), 467
Lorazepam, pentobarbital, and pentazocine, respiratory effects of (Gasser et al.), 170

M

Man, animals and, interaction of sudoxicam and aspirin in (Wiseman et al.), 441
Marihuana effects, attempts to correlate, after THC and 11-OH-THC in rapid and slow hydroxylators, as determined with antipyrine and phenylbutazone (Hollister and Gillespie), 714
  combined with secobarbital (Dalton et al.), 298
  evaluation, cannabinol interfering factor in (Hollister and Gillespie), 80
  and placebo marihuana smoking, effects of, on hemodynamics in coronary disease (Prakash et al.), 90
Medical biostatistics, proposal for core curriculum in, 127
  students, teaching statistics to (Feinstein), 121
Melengestrol, progestational steroid, suppression of cortisol by (Nugent et al.), 338
6-Mercaptopurine-adriamycin, combination, in refractory adult acute leukemia (Rodriguez et al.), 462
Metabolic availability of ascorbic acid, factors influencing (Burr), 238 (Correspondence)
Metabolism, antipyrine, in man; influence of age, alcohol, caffeine, and smoking (Vestal et al.), 425
  circadian changes in rate of, adrenocorticosteroids involved in (Shively and Vesell), 413
  drug, effects of tricyclic antidepressants on (Pond et al.), 191
  effects of individual variations in (Wilkinson and Shand), 377 (Commentary)
  first-pass, of nortriptyline in man (Gram and Overø), 305
  in man, elimination of antipyrine from saliva as measure of (Welch et al.), 249
Metabolism—cont'd
  pharmacokinetics and, of lidocaine in patients with renal failure (Collinsworth et al.), 59
  salicylate, correlation of plateau serum salicylate level with rate of (Gupta et al.), 350
Metabolites, acetaminophen, in anephric patients, hemodialysis major route of elimination (Øie et al.), 680
  hydrazine, possible relation of increased incidence of isoniazid hepatitis in rapid acetylators to (Mitchell et al.), 70
Methadone in man; pharmacokinetic and excretion studies in acute and chronic treatment (Verebely et al.), 180
Minoxidil, oral, method for achieving blood pressure control expeditiously with (O'Malley et al.), 39
Monoamine oxidase, kinetics of octopamine in relation to (Murphy et al.), 587
  and L-aromatic amino acid decarboxylase, interactions of levodopa with inhibitors of (Teychenne et al.), 273
Morphine, nefopam and, in man (Sunshine and Laska), 530
Muscle, human cardiac, electrophysiologic effects of glucagon on (Prasad et al.), 22
Myocardial ischemia, effect of acidosis on patients with (Holsinger and Miscia), 594

N

Nabilone, clinical pharmacology of, cannabinol derivative (Lemberger and Rowe), 720
N-acetyl procainamide, absolute bioavailability in man of, determined by novel stable isotope method (Strong et al.), 613
Natriuretic response to furosemide, effect of dosage regimen on (Wilson et al.), 165
Nausea and vomiting, oral benzquinamide in treatment of (Moertel et al.), 554
Nefopam and morphine in man (Sunshine and Laska), 530
  respiratory effects of (Gasser and Bellville), 175
Nortriptyline, first-pass metabolism of, in man (Gram and Overø), 305

O

Octopamine, occurrence, transport, and storage of, in human thrombocytes (Murphy et al.), 587
Opiate effects of acetylmethadol principally due to noracetylmethadol (Kaiko and Inturrisi), 96
Oral minoxidil, method for achieving blood pressure control expeditiously with (O'Malley et al.), 39
Oxygen transport by blood, acceleration of, for relief of angina (Holsinger and Miscia), 594

P

Patient package inserts, nature, notions, and needs (Joubert and Lasagna), 507 (Commentary)
toward rational patient package insert (Joubert and Lasagna), 663 (Commentary)
Pediatric trials, panel on, in clinical trials of drugs (Mirkin et al.), 657
Penfluridol steady-state kinetics in psychiatric patients (Cooper et al.), 325
Pentazocine, butorphanol and, in patients with severe postoperative pain (Dobkin et al.), 547
Pentobarbital, flurazepam and, effectiveness of hypnotic drugs with prolonged use (Kales et al.), 356
lorazepam, and pentazocine, respiratory effects of (Gasser et al.), 170
Perhexiline, electrophysiologic properties of (Vera et al.), 623
Pharmaceutical industry, clinical trials of drugs from viewpoint of (Peltier), 637
Pharmacokinetic(s) of ampicillin in cirrhosis (Lewis and Jusko), 475
digoxin; role of renal failure in dosage regimen design (Koup et al.), 9
and excretion studies in acute and chronic treatment; methadone in man (Verebely et al.), 180
factors, lack of correlation between plasma guanethidine levels and adrenergic blockade related to (Walter et al.), 571
of hexobarbital in acute hepatitis and after apparent recovery (Briemer et al.), 433
of indomethacin (Alván et al.), 364
and metabolism of lidocaine in patients with renal failure (Collinsworth et al.), 59
single-dose, bioavailability and, of intramuscular phenytoin (Kostenbauder et al.), 449
Pharmacologic action, disposition of acetylmethadol in relation to (Kaiko and Inturrisi), 96
Phenacetin, antipyrine, aminopyrine, and, studies on disposition of, using plasma, saliva, and urine (Vesell et al.), 259
half-life in man, acetaminophen and, temporal variations in (Shively and Vesell), 413
Phenobarbital, carbamazepine, phenytoin, and, treatment with, in preventing epileptic seizures (Cereghino et al.), 733
concentrations, phenytoin and, in saliva and plasma measured by radioimmunoassay (Cook et al.), 742
fluroxene toxicity induced by (Munson et al.), 687
prior treatment with, cause of intensified toxicity in fluroxene anesthesia in rhesus monkeys (Munson et al.), 687
Phenylbutazone, antipyrine and, attempts to correlate marihuana effects after THC and 11-OH-THC in rapid and slow hydroxylators, as determined with (Hollister and Gillespie), 714
and vitamin D_3, half-life of altered by oral steroid contraceptive therapy (Carter et al.), 700
Phenytoin, carbamazepine, and phenobarbital, treatment with, in preventing epileptic seizures (Cereghino et al.), 733
complex pattern of disposition of, in severe intoxication (Pruitt et al.), 112
hemodialysis of, in uremic patient (Adler et al.), 65
intramuscular, bioavailability and single-dose pharmacokinetics of (Kostenbauder et al.), 449
metabolism, changes in, associated with use of amitriptyline or nortriptyline (Pond et al.), 191
and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay (Cook et al.), 742
Phosphorus, effect of hydrochlorothiazide on, during treatment with diphosphonate (Recker), 345
Physiological approach to hepatic drug clearance (Wilkinson and Shand), 377 (Commentary)
Plasma clearance, effect of oral contraceptives on (Carter et al.), 700
concentrations and time-course of beta blockade due to propranolol (McDevitt and Shand), 708
flow, renal (PAH clearances), decreases in inulin and, after intravenous diazepam (Guignard et al.), 401
guanethidine levels, relationship of, to adrenergic blockade (Walter et al.), 571
levels, clinical presentation and, tricyclic antidepressant overdose (Spiker et al.), 539
propranolol concentrations, spuriously low, resulting from blood collection methods (Cotham and Shand), 535
protein binding, decreased, of diazoxide in uremia (O'Malley et al.), 53
and saliva, levels of antipyrine in, and use for antipyrine studies in man (Welch et al.), 249
phenytoin and phenobarbital concentrations in, measured by radioimmunoassay (Cook et al.), 742
studies on disposition of antipyrine, aminopyrine, and phenacetin using (Vesell et al.), 259
Polymorphism, acetylation, of sulfapyridine in patients with ulcerative colitis and Crohn's disease (Das and Eastwood), 514

Potassium, total body, and 24-hour creatinine excretion in healthy males (Turner and Cohn), 405
Procainamide in clinical use, N-acetylprocainamide preferable to (Strong et al.), 613
Prochlorperazine compared to oral benzquinamide in treatment of nausea and vomiting (Moertel et al.), 554
Propantheline, biopharmaceutic influences on anticholinergic effects of (Gibaldi and Grundhofer), 457
Propranolol in angina pectoris (Miller et al.) 598
  comparison with timolol as beta blocker (Franciosa and Freis), 158
  concentrations, plasma, spuriously low, resulting from blood collection methods (Cotham and Shand), 535
  in hypertensive dialysis patients, efficacy and compliance (Briggs et al.), 606
  plasma concentrations and time-course of beta blockade due to (McDevitt and Shand), 708
  timolol and, comparison of cardiac effects of (Achong et al.), 278
Prorenoate and spironolactone in normal man, relative potency of (Ramsay et al.), 391
Prostaglandin biosynthesis, effects of arachidonate on (Seyberth et al.), 521
Protein binding, decreased plasma, of diazoxide in uremia (O'Malley et al.), 53
Psychiatric disturbances, octopamine in (Murphy et al.), 587
  patients, penfluridol steady-state kinetics in (Cooper et al.), 325
PTG, new antineoplastic epipodophyllotoxin (Creaven and Allen), 227
Public service drugs and new uses for old drugs, panel on (Atkinson et al.), 659

Q

Quinine-induced alterations in drug disposition (Berlin et al.), 670

R

Radioimmunoassay, phenytoin and phenobarbital concentrations in saliva and plasma measured by (Cook et al.), 742
Reflections in crystal ball (Lasagna), 1 (Commentary)
Renal clearance of canrenoate in normal man (Hofmann et al.), 748
  failure, pharmacokinetics and metabolism of lidocaine in patients with (Collinsworth et al.), 59
    prediction of drug dosage in patients with, using data derived from normal subjects (Welling et al.), 45
    role of, in dosage regimen design; digoxin pharmacokinetics (Koup et al.), 9
Renal—cont'd
  function, effect of intravenous diazepam on (Guignard et al.), 401
Renin release in man, alpha and beta adrenergic-induced (Leenen et al.), 31
Respiratory effects of lorazepam, pentobarbital, and pentazocine (Gasser et al.), 170
  of nefopam (Gasser and Bellville), 175

S

Salicylate, distribution of, between neonatal and maternal serum at diffusion equilibrium (Levy et al.), 210
  level, plateau serum, correlation of, with rate of salicylate metabolism (Gupta et al.), 350
Saliva, elimination of antipyrine from, as measure of metabolism in man (Welch et al.), 249
  and plasma, phenytoin and phenobarbital concentrations in, measured by radioimmunoassay (Cook et al.), 742
  studies on disposition of antipyrine, aminopyrine, and phenacetin using (Vesell et al.), 259
Salivary excretion of amobarbital in man (Inaba and Kalow), 558
Scopolamine, effects of repeated doses of, on electroencephalographic stages of sleep in normal volunteers (Sagalés et al.), 727
Secobarbital, effects of marihuana combined with (Dalton et al.), 298
  triazolam compared with, as hypnotic for initially depressed insomniacs (Rickels et al.), 315
Serum amobarbital, correlation between salivary and (Inaba and Kalow), 558
  digoxin concentrations, serial, and quantitative electrocardiographic changes (Joubert et al.), 757
  neonatal and maternal, distribution of salicylate between, at diffusion equilibrium (Levy et al.), 210
  salicylate level, plateau, correlation of, with rate of salicylate metabolism (Gupta et al.), 350
Sex differences in intramuscular absorption and bioavailability of cephradine (Vukovich et al.), 215
Skeletal muscle, reduction of enzyme efflux from, by diethylstilbestrol (Dempsey et al.), 104
Sleep, electroencephalographic stages of, in normal volunteers, effects of repeated doses of scopolamine on (Sagalés et al.), 727
Smoking, age, alcohol, caffeine, and, influence of, antipyrine metabolism in man (Vestal et al.), 425

Smoking—cont'd
placebo marihuana and marihuana, effects of, on hemodynamics in coronary disease (Prakash et al.), 90
Spironolactone, prorenoate and, relative potency of (Ramsay et al.), 391
Statistics, teaching, to medical students (Feinstein), 121
Steroid contraceptive therapy, oral, shown to alter half-life of antipyrine, phenylbutazone, and vitamin D_3 (Carter et al.), 700
progestational, melengestrol, suppression of cortisol by (Nugent et al.), 338
Sudoxicam and aspirin in animals and man, interaction of (Wiseman et al.), 441
Sulfapyridine, acetylation polymorphism of, in patients with ulcerative colitis and Crohn's disease (Das and Eastwood), 514

T

Teaching statistics to medical students (Feinstein), 121
Tetrahydrocannabinol, delta-9-, and codeine, analgesic properties of (Noyes et al.), 84
interactions in man of; cannabinol and cannabidiol (Hollister and Gillespie), 80
prolonged, cardiovascular effects of (Benowitz and Jones), 287
Thrombocytes, human, occurrence, transport, and storage of octopamine in (Murphy et al.), 587
Ticlopidine, effects of, new platelet aggregation inhibitor in man (Thebault et al.), 485
Timolol in hypertensive patients, normal cardiac output during beta blockade with (Franciosa and Freis), 158
and propranolol, comparison of cardiac effects of (Achong et al.), 278
Tolbutamide metabolism, changes in, associated with use of amitriptyline or nortriptyline (Pond et al.), 191
Toxicity, adjustments in digoxin dosage necessary to avoid (Koup et al.), 9
fluroxene, induced by phenobarbital (Munson et al.), 687
Triazolam in insomniac family practice patients (Rickels et al.), 315
Tricyclic antidepressants, effects of, on drug metabolism (Pond et al.), 191

U

Ulcerative colitis and Crohn's disease, acetylation polymorphism of sulfapyridine in patients with (Das and Eastwood), 514
Uremia, decreased plasma protein binding of diazoxide in (O'Malley et al.), 53
Uremic patient(s), hemodialysis of phenytoin in (Adler et al.), 65
prediction of drug dosage in (Welling et al.), 45
Urinary electrolyte, little change in induced by canrenoate in absence of hyperaldosteronism (Hofmann et al.), 748
Urine, studies on disposition of antipyrine, aminopyrine, and phenacetin using (Vesell et al.), 259

V

Vitamin D_3, antipyrine, phenylbutazone, and, half-life of altered by oral steroid contraceptive therapy (Carter et al.), 700
Vomiting, nausea and, oral benzquinamide in treatment of (Moertel et al.), 554

W

Warfarin, metabolism, changes in, associated with use of amitriptyline or nortriptyline (Pond et al.), 191